GlassScriptPhysician profile
Sajid Khan
NPI 1568946820
$4,556.90
in general payments reported to CMS, 2019-2025
34 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $51.57 · 2022: $344 · 2023: $1,290 · 2024: $698 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414 · Travel and Lodging: $342 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,414.00 |
| Travel and Lodging | $342.39 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $612.87 | 2023-2025 | Minimed 780g, Turbohawk, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $542.95 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $408.40 | 2022-2024 | Freestyle Libre 3, Aveir |
| Amgen INC. | $395.43 | 2024-2025 | Tepezza, Evenity |
| Lilly USA, LLC | $301.03 | 2022-2025 | Mounjaro, Jardiance, Lyumjev |
| Dexcom, INC. | $203.23 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.85 | 2023-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $153.88 | 2019-2023 | Farxiga |
| Lifescan, INC. | $147.90 | 2022-2023 | |
| Horizon Therapeutics Plc | $136.44 | 2022-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $135.60 | 2022-2025 | |
| Corcept Therapeutics | $130.85 | 2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $119.10 | 2022-2025 | Gvoke Hypopen |
| Alkermes, INC. | $118.75 | 2019 | |
| Amarin Pharma, INC. | $117.96 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $117.35 | 2022-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $114.84 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $66.40 | 2022-2023 | Unithroid |
| Nevro Corp. | $64.77 | 2023 | Senza |
| Sanofi-Aventis U.S. LLC | $54.84 | 2023-2024 | |
| Abiomed | $48.33 | 2024 | Impella |
| Recordati_rare_diseases_inc. | $48.08 | 2023 | Isturisa, Signifor Lar |
| Averitas Pharma INC. | $46.76 | 2025 | Qutenza |
| Mannkind Corporation | $42.50 | 2025 | |
| Novartis Pharmaceuticals Corporation | $41.38 | 2024-2025 | |
| Antares Pharma, INC. | $37.79 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Cequr Corporation | $34.13 | 2025 | Cequr Simplicity |
| Currax Pharmaceuticals LLC | $28.96 | 2020 | |
| Kyowa Kirin, INC. | $26.16 | 2023 | Crysvita |
| Ibsa Pharma INC. | $20.82 | 2023 | Tirosint, Licart |
| Halozyme INC | $17.50 | 2023 | |
| Abbvie INC. | $17.33 | 2022 | |
| Pfizer INC. | $15.13 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.59 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajid Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.